To determine the association between catechol-O-methyltransferase (COMT) genotype and 6-m walk time and to determine whether these associations are quadratic in nature, similar to previously reported U-shaped associations between dopamine and gait and cognition. DESIGN: Prospective cohort study. SETTING: Health, Aging and Body Composition Study. PARTICIPANTS: Black (n = 850) and white (n = 1,352) men and women with a mean age of 73.5 AE 2.85 at baseline. MEASUREMENTS: Mixed models were used to assess the association between the COMT genotype and 6-m walk time, cross-sectionally and longitudinally over 10 years. Models were assessed unstratified and stratified according to race because allele distributions were different between white and black participants. RESULTS: There was a significant U-shaped association between COMT genotype and 6-m walk time: those with higher (Val/Val) and lower (Met/Met) dopamine slowed more over 10 years (0.22 AE 0.02 seconds per visit and 0.23 AE 0.02 seconds per visit, respectively) than those with the intermediate (Met/Val) dopamine (0.20 AE 0.02 seconds per visit) (P = .005). Stratified results showed a significant relationship in black (P = .01) but not white (P = .15) participants.
D
opaminergic systems have been identified as a contributor to gait speed and mobility deficits in individuals with Parkinson's disease, 1, 2 but not in community-dwelling older adults free of neurological disease, although there is a documented relationship between higher dopamine levels and better attention and executive function, 3, 4 which are both related to mobility. [5] [6] [7] Furthermore, dopamine release in the brain modulates connections to the prefrontal cortex (PFC), 8 which may enhance gait performance 9,10 because of its involvement in attention and executive control processes. In addition, declines in dopamine and mobility are both associated with older age and changes in the brain with aging. 11, 12 Some positron emission tomography (PET) studies have demonstrated associations between low striatal dopamine levels and risk of slip perturbation and falls, poor balance, and slow gait in small samples of older adults. [13] [14] [15] [16] One challenge is that dopamine levels, especially within the brain, are not often available in epidemiological studies.
Catechol-O-methyltransferase (COMT) is a dopamineregulating enzyme in the brain, particularly the PFC. The COMT val 158 met polymorphism determines levels of the COMT enzyme and, consequently, dopamine levels in the brain. 1 In the absence of actual dopamine levels, the COMT val 158 met polymorphism provides an excellent surrogate. The Met allele, associated with lower COMT, results in slower clearance and higher tonic dopamine levels, particularly in the PFC. 1, 17 Conversely, the Val allele has faster clearance and lower tonic dopamine levels. 1, 17 The val 158 met polymorphism was found to be associated with attention, executive function, [18] [19] [20] and gait speed in a crosssectional study of older adults without dementia. 21 Results indicated that the Met/Val genotype was associated with faster gait speed than the Met/Met genotype because of a U-shaped association between dopamine level and gait speed. 21 A similarly shaped association was also reported between dopamine and cognition; individuals with intermediate levels of dopamine performed better than those with high or low levels. [21] [22] [23] More studies are needed to investigate the longitudinal association between the COMT val 158 met polymorphism to see whether the relationship exists in other populations and over time and whether the quadratic relationship is the same.
The objectives of this study were to determine the association between the COMT genotype and 6-m walk time, cross-sectionally and longitudinally, and to determine whether these associations are quadratic. Another objective was to determine whether associations were robust to adjustments for demographic and health-related factors that may affect the association between dopamine and gait changes.
METHODS

Study Population
Community-dwelling white and black older adults were enrolled in the Health, Aging and Body Composition prospective cohort study beginning in 1997. At baseline, 3,075 adults were aged 70 to 79 and lived in Memphis, Tennessee, or Pittsburgh, Pennsylvania. Participants were recruited from a random sample of Medicare-eligible adults within designated ZIP codes and were eligible if they reported no difficulties performing activities of daily living, walking one-quarter of a mile, or climbing 10 steps without resting. Follow-up visits were conducted yearly, with information no more-detailed performance-based measures collected at Visits 4, 6, and 10. The institutional review boards of the participating institutions approved this study, and all participants provided written informed consent.
Analytical Cohort
The analytical sample was defined as participants who had baseline 6-m walk time data, completed a 6-m walk at at least one other clinic visit, and had complete data on all covariates of interest (n = 2,202 of the original 3,075). Participants were excluded because of missing COMT information (n = 220), baseline 6-m walk time (n = 27), or a second measure of walk time or covariate of interest (n = 626). All 2,202 participants contributed to all analyses; all had baseline 6-m walk time data, 1,786 had Visit 4 data, n = 1,578 had Visit 6 data, and n = 1,080 had Visit 10 data.
COMT Genotype
COMT was measured from genomic deoxyribonucleic acid extracted from ethylenediaminetetraacetic acid-anticoagulated whole blood using standard methods (Gentra Systems, Minneapolis, MN), and polymerase chain reaction-based COMT genotyping, as previously described. 24 
Six-m Walk Time
Time to walk 6-m, a modification of the short walk used in many epidemiological studies, was assessed at Years 1, 4, 6, and 10. Participants were asked to walk 6 m, on a marked, obstacle-free course in a long corridor, at least 122 cm wide, at usual pace. Participants started behind the start line and were instructed to walk through the finish line at their usual pace. Time was measured from the first footfall over the starting line to the first footfall across the finish line to the nearest 0.01 seconds. Participants completed two trials at each visit, and the fastest time was recorded.
Modified Physiologic Index
The Modified Physiologic Index (MPI) was designed to use several widely available components to assess a range of physiologic systems, including vasculature, lungs, kidneys, brain, and glucose metabolism, and act as a measure of multisystem comorbidity to predict mortality and disability more accurately than age. 25 It has previously been associated with gait speed at baseline and over time 26 and was chosen as a primary covariate to represent comorbidity. Contributing components included blood pressure to assess vasculature, spirometry to measure forced vital capacity to assess the lungs, the Digit Symbol Substitution Test to assess brain health, serum fasting glucose to assess glucose metabolism, and serum cystatin-C to assess kidney function. 25 Details on the creation of the MPI have previously been described. 25 It is a continuous measure grouped into scores of 0 to 2 (healthiest), 3 to 4, 5 to 6, and 7 to 10 (unhealthiest). 25 
Covariates
At baseline, demographic data were recorded on selfreported age, race, sex, and education. European ancestry admixture was measured in the Health, Aging and Body Composition Study for genetic analyses. 27, 28 Admixture is approximated using STRUCTURE and has previously been described. 29 Baseline height and weight were used to calculate body mass index (BMI, kg/m 2 ). Knee extensor strength was measured concentrically at 60°per second using an isokinetic dynamometer (125 AP Dynamometer, Kin-Com, Harrison, TN). Quadriceps strength was calculated as the mean maximal torque (Nm) from the three best trials. 30 Sex-specific median cutoffs (men, 132.27 Nm; women, 81.84 Nm) were used to classify quadriceps strength. 30 Information was recorded on self-reported knee pain in either knee on most days or for one month or more in the past year. Physical activity was estimated as kcal/kg/week spent walking and climbing stairs, assessed using a questionnaire. 31 
Statistical Analyses
An a priori decision to conduct all analyses unstratified and then stratified according to race was based on previous research showing strong race-specific differences in the distribution of COMT, 24 as the distribution in the current study sample evidenced, and strong differences in 6-m walk time according to race (t-test statistic = À27.27, P < .001) and European ancestry (F-test statistic = 11.81, P < .001). The decision to report unstratified results was based a previous cross-sectional study so comparisons could be made more easily. 21 Chi-square tests, analysis of variance, and independent-samples t-tests were used to examine the cross-sectional associations between demographic characteristics according to COMT genotype at baseline. Pairwise comparisons and overall tests were conducted, consistent with prior work. 21 Mixed models were used to assess cross-sectional and longitudinal associations between COMT genotype and 6-m walk time and to predict mean 6-m walk time at baseline and over time according to COMT genotype. In unstratified analyses, Model 1 was adjusted for race and European ancestry, which were kept in all subsequent models and additionally adjusted for MPI (Model 2); age, sex, and BMI (Model 3); and knee pain and weak quadriceps strength (Model 4). Similar adjustments were made in race-stratified analyses, with the exception of race and European ancestry admixture as covariates.
COMT genotypes are presented and compared as predicted baseline mean 6-m walk times and annualized slopes of change. Model checks to ensure fit were rigorous and included assessing the interaction of all covariates with time and all two-way interactions; only significant interactions were included in final models. The quadratic association between COMT and 6-m walk time at baseline and over time was assessed with an interaction of COMT*COMT and COMT*COMT*time. Linear and quadratic terms were included in all models, and p-values for each are reported. All analyses were conducted with SAS version 9.4 (SAS Institute, Inc., Cary, NC).
RESULTS
Of the 2,202 participants in this analytical sample, 850 (38.6%) were black, and 1,139 (51.7%) were female, and average age at baseline was 73.5 AE 2.8. There were 422 (19.2%) with the Met/Met genotype, 1,073 (48.7%) with the Met/Val genotype, and 707 (32.1%) with the Val/Val genotype. Participants were followed for a maximum of 10 years (7.85 AE 1.99 years for black participants, 7.90 AE 2.08 years for white participants). Participants excluded from analyses were more likely to be black (49.4% vs 38.6%, P < .001) and, for those with available data, were less likely to be in the healthiest MPI category (11.6% vs 19.2%, P = 0.03) but did not differ in other characteristics, including mobility disability at baseline. Participants in the analytical sample were less likely to die during follow-up (38% vs 55%, P < .001). Black participants were more likely to die (52.4% vs 47.6%, P < .001).
Breakdown (Table 1 ). There were no significant differences according to genotype in sex, age, quadriceps strength, or knee pain. There was less heterogeneity according to genotype for these characteristics when stratified according to race (Table 1) .
At baseline, in mixed models, there was no significant relationship with COMT and 6-m walk time in unstratified (Table 2) , or stratified analyses (Table 3) Table 2 ) remained significant after adjustment for all covariates.
In stratified analyses, there was no significant relationship between COMT and 6-m walk time over 10 years in white older adults (Table 3) , but in black older adults, over 10 years, those with a Val/Val genotype slowed by an average of 0.18 AE 0.01 seconds per visit, those with a Met/Val genotype slowed by 0.14 AE 0.01 seconds per visit, and those with a Met/Met genotype slowed by an average of 0.21 AE 0.03 seconds per visit. This relationship was statistically significant and quadratic in nature (P = .01, Table 3, Figure 1 ) and remained statistically significant after adjustment for all covariates (Table 3) .
DISCUSSION
To the knowledge of the authors, this is the first longitudinal study to examine the association between COMT and gait speed in community-dwelling older adults. In unstratified and race-stratified analyses, participants with homozygous genotypes had a greater slowing in gait speed over 10 years than those with a Met/Val genotype.
These cross-sectional results differ slightly from those of a previous cross-sectional study that found that individuals with the Met/Val genotype were faster than those with the Met/Met genotype but found no differences between the Val/Val and Met/Met genotypes. 21 The current study found a significant cross-sectional association in univariate analyses, although the association diminished after adjustment for race and European ancestry, which the authors believe explains the discrepancy, because the previous study did not report distribution of COMT according to race or ethnicity or adjust the models for race and ethnicity. 21 Participants in the prior study were also approximately 5 years older, on average, than participants in the current study, so significant cross-sectional results might reflect the longitudinal differences seen according to genotype.
There are several mechanisms that might underlie an association between COMT and decline in gait speed. COMT regulates dopamine levels primarily in the PFC and affects attention and executive function, 3,4 which are Pairwise P-values calculated using the Met/Met group serving as the reference group. SD = standard deviation; BMI = body mass index; MPI = Modified Physiologic Index.
JAGS SEPTEMBER 2017-VOL. 65, NO. 9 COMT GENOTYPE AND GAIT SPEED CHANGESdirectly related to mobility and gait speed. [5] [6] [7] As dopamine levels decline with age, and dopamine release modulates connections to the PFC, less-efficient PFC function may result in slower gait. 9, 10 Genetic polymorphisms influencing dopamine, including COMT, can change functionality and plasticity in the dopaminergic system, 32-34 affecting executive control, 23, 35, 36 and could cause mobility declines. The current study found a stronger association in black participants, in spite of a larger sample size of whites. This might be because black older adults are more vulnerable to gait declines over time. 37 Vulnerability to gait speed declines over time may also explain the lack of significant cross-sectional results; over 10 years, all participants, who were relatively healthy at baseline, become more vulnerable to gait changes, and thus, meaningful declines and differences were seen.
A U-shaped association was found, consistent with other studies showing that homozygous groups perform worse than heterozygotes. 21, 23 The U-shaped association may demonstrate an interaction with gene and environment, specifically, COMT and the aging brain, such that those who benefit from high dopamine in early age may not maintain these benefits as they age and vice versa. For example, Met carriers, shown to have better executive function and working memory, especially as young adults, 20, 38, 39 also have lower gray matter PFC volume as older adults, which is related to poorer cognitive performance. 40 An association between COMT and maintained gait speed in those with loss of structural integrity would support this idea. Another potential explanation is that dopaminergic systems have effects on two cognitive processes-sustained attention on executively demanding tasks and cognitive flexibility for transient tasks-which COMT influences differently. 21, 39 This theory, summarized by the tonic phases dopamine hypothesis 1 , briefly states that dopamine is released in two ways: one in phasic, short bursts in response to an environmental, cognitive, or motor task (cognitive flexibility tasks) and one in a consistent, lowlevel background manner (sustained attention tasks). The quadratic associations exemplify this theory because Val allele carriers have higher enzymatic activity, reducing the constant background levels of dopamine and creating a low threshold for phasic dopamine bursts in COMT Val carriers, making carriers of this allele worse at sustained attention tasks but better at cognitive flexibility tasks. Conversely, Met allele carriers have higher background dopamine levels because they have lower enzymatic activity and require higher phasic dopamine to exert an effect, thus performing better on sustained attention but worse on cognitive flexibility tasks. 21, 39 More work is needed to determine the underlying cause of this U-shaped relationship and why it persists for multiple outcomes. Although a single gene variant would not b e expected to have a large effect on a complex behavior such as gait speed, and the current study results reflect this, because the effect sizes are small, these findings suggest that the dopaminergic system, specifically COMT, is important for mobility in older age.
This study had several strengths, including measurement of 6-m walk time at four points over 10 years. The sample size was large, providing ample analytical power for this mixed-model approach. Measurement of numerous comorbidities and demographic data allowed a large number of covariates and confounders to be investigated, including the MPI, previously established as a predictor of morbidity and functional disability in healthy older adults. 25 Finally, the differences found are believed to be small but clinically meaningful based on previous research; 41, 42 after converting the changes from 6-m walk time to gait speed changes per year, the results indicate that black participants with a Met/Met genotype slowed by 0.04 m/s more than those with the Met/Val genotype and that black participants with the Val/Val genotype slowed by 0.02 m/s more than those with the Met/Val genotype. Although these differences are small, gait speed changes as small as 0.04 to 0.06 m/s per year have been reported to have clinical significance. 41, 42 As expressed earlier, because only one gene, and how it predicts a multifaceted process, was being examined, these small effects are in line with what would be expected from a single gene, and further investigation of the effects of dopaminergic pathways on gait is warranted. There are also several weaknesses that should be considered when interpreting these results. Adults were all well functioning and community dwelling at baseline, represented persons who survived a minimum of 3 years after baseline and on average much longer, and were significantly less likely to die over 10 years than participants not included in our analytic sample, so results may not be generalizable to all older adults-for example, nursing home populations. To investigate how missing data affected the results, a sensitivity analysis was performed to include all previously excluded participants who were missing health or demographic covariates, except for race and European ancestry, because it was felt that those adjustments had to be kept. Results and conclusions from this sensitivity analysis of 2,855 participants did not significantly change (data not shown). Only COMT, which regulates tonic dopamine levels in the brain, could be examined, but examining pet of the molecular integrity of dopaminergic systems in the brain would be a useful next step in this research.
A significant U-shaped association was found between COMT and gait speed over 10 years. Those with homozygous COMT genotypes were more likely to experience gait decline over 10 years than those with a Met/Val genotype. Future studies should investigate potential underlying mechanisms of the association between COMT and change in gait speed, including PET and magnetic resonance imaging studies to examine structural changes associated with COMT genotype and gait speed. Imaging studies may further elucidate the dynamic nature of the relationship and help provide a better explanation of the shape of this relationship and whether it is due to dual functionality of dopamine which is important for sustained attention and cognitive flexibility. Replicating results in independent samples with genotyping arrays and including more dopamine-related genes would be useful.
